This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of +66.67% and +10.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 14.29% and 4.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 0% and 11.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?
by Zacks Equity Research
Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 57.14% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Sea Limited to Post Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
SE's fourth-quarter performance is likely to have benefited from strong Shopee and SeaMoney growth. Competition and FX volatility are expected to have hurt profitability.
Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Verrica Pharmaceuticals (VRCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 68.75% and 313.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Xeris Biopharma (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Xeris Biopharma (XERS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 33.33% and 5.09%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of -20.83% and 10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 9.09% and 2.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 52.63% and 52.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -16.67% and 2.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?